GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Total Inventories

Generex Biotechnology (Generex Biotechnology) Total Inventories : $0.23 Mil (As of Apr. 2021)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Total Inventories?

Generex Biotechnology's total inventories for the quarter that ended in Apr. 2021 was $0.23 Mil. Generex Biotechnology's average total inventories from the quarter that ended in Jan. 2021 to the quarter that ended in Apr. 2021 was $0.43 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Generex Biotechnology's Net-Net Working Capital per share for the quarter that ended in Apr. 2021 was $-0.86.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Generex Biotechnology's Days Inventory for the three months ended in Apr. 2021 was 587.59.

Inventory Turnover measures how fast the company turns over its inventory within a year. Generex Biotechnology's Inventory Turnover for the quarter that ended in Apr. 2021 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Generex Biotechnology's Inventory-to-Revenue for the quarter that ended in Apr. 2021 was 20.24.


Generex Biotechnology Total Inventories Historical Data

The historical data trend for Generex Biotechnology's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Total Inventories Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.36 0.74

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.74 0.72 0.62 0.23

Generex Biotechnology Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Generex Biotechnology  (OTCPK:GNBTQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Generex Biotechnology's Net-Net Working Capital Per Share for the quarter that ended in Apr. 2021 is

Net-Net Working Capital Per Share (Q: Apr. 2021 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.675+0.75 * 0.052+0.5 * 0.232-94.081
-0-8.176)/116.279
=-0.86

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Generex Biotechnology's Days Inventory for the three months ended in Apr. 2021 is calculated as:

Days Inventory=Average Total Inventories (Q: Apr. 2021 )/Cost of Goods Sold (Q: Apr. 2021 )*Days in Period
=0.425/0.066*365 / 4
=587.59

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Generex Biotechnology's Inventory Turnover for the quarter that ended in Apr. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Apr. 2021 ) / Average Total Inventories (Q: Apr. 2021 )
=0.066 / 0.425
=0.16

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Generex Biotechnology's Inventory to Revenue for the quarter that ended in Apr. 2021 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Apr. 2021 ) / Revenue (Q: Apr. 2021 )
=0.425 / 0.021
=20.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Generex Biotechnology Total Inventories Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus